Free Trial

Wave Life Sciences (WVE) Competitors

+0.25 (+4.45%)
(As of 02:13 PM ET)


Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include UroGen Pharma (URGN), Akebia Therapeutics (AKBA), RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), Geron (GERN), Rhythm Pharmaceuticals (RYTM), Bausch Health Companies (BHC), Agios Pharmaceuticals (AGIO), PTC Therapeutics (PTCT), and Deciphera Pharmaceuticals (DCPH). These companies are all part of the "pharmaceutical preparations" industry.

Wave Life Sciences vs.

Wave Life Sciences (NASDAQ:WVE) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.

Wave Life Sciences has higher revenue and earnings than UroGen Pharma. Wave Life Sciences is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wave Life Sciences$113.31M6.07-$57.51M-$0.52-10.81
UroGen Pharma$82.71M4.80-$102.24M-$3.40-4.98

UroGen Pharma received 10 more outperform votes than Wave Life Sciences when rated by MarketBeat users. Likewise, 73.51% of users gave UroGen Pharma an outperform vote while only 67.31% of users gave Wave Life Sciences an outperform vote.

Wave Life SciencesOutperform Votes
Underperform Votes
UroGen PharmaOutperform Votes
Underperform Votes

Wave Life Sciences has a net margin of -54.61% compared to UroGen Pharma's net margin of -123.74%.

Company Net Margins Return on Equity Return on Assets
Wave Life Sciences-54.61% N/A -26.24%
UroGen Pharma -123.74%N/A -62.48%

In the previous week, Wave Life Sciences had 3 more articles in the media than UroGen Pharma. MarketBeat recorded 4 mentions for Wave Life Sciences and 1 mentions for UroGen Pharma. UroGen Pharma's average media sentiment score of 1.89 beat Wave Life Sciences' score of 0.62 indicating that UroGen Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Wave Life Sciences Positive
UroGen Pharma Very Positive

Wave Life Sciences presently has a consensus target price of $13.17, indicating a potential upside of 134.28%. UroGen Pharma has a consensus target price of $51.17, indicating a potential upside of 202.22%. Given UroGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe UroGen Pharma is more favorable than Wave Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Wave Life Sciences
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
UroGen Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)

Wave Life Sciences has a beta of -1.12, suggesting that its share price is 212% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by company insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Wave Life Sciences beats UroGen Pharma on 9 of the 17 factors compared between the two stocks.

Get Wave Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WVE vs. The Competition

MetricWave Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$688.28M$7.07B$5.02B$8.66B
Dividend YieldN/A2.73%5.25%4.04%
P/E Ratio-10.8110.39111.5114.85
Price / Sales6.07334.262,158.8189.56
Price / CashN/A32.9133.7132.55
Price / Book14.055.964.904.67
Net Income-$57.51M$142.65M$105.41M$213.49M
7 Day Performance2.74%13.33%124.10%8.42%
1 Month Performance-9.79%10.73%127.79%7.36%
1 Year Performance39.11%1.17%132.22%3.16%

Wave Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UroGen Pharma
3.9301 of 5 stars
3.93 / 5 stars
+84.2%$384.35M$82.71M-4.82204Positive News
Akebia Therapeutics
3.2469 of 5 stars
3.25 / 5 stars
+18.9%$226.37M$194.62M-4.70167Short Interest ↑
RAPT Therapeutics
3.6424 of 5 stars
3.64 / 5 stars
-83.4%$117.27M$1.53M-1.09126Positive News
Marinus Pharmaceuticals
3.7698 of 5 stars
3.77 / 5 stars
4.2127 of 5 stars
4.21 / 5 stars
+46.3%$2.73B$240,000.00-13.14141Short Interest ↓
News Coverage
Positive News
Rhythm Pharmaceuticals
2.0658 of 5 stars
2.07 / 5 stars
+214.0%$2.71B$77.43M-9.59226Short Interest ↓
Positive News
Bausch Health Companies
4.0129 of 5 stars
4.01 / 5 stars
Agios Pharmaceuticals
2.242 of 5 stars
2.24 / 5 stars
+68.6%$2.47B$26.82M-6.88383Short Interest ↓
Positive News
PTC Therapeutics
3.8652 of 5 stars
3.87 / 5 stars
-15.1%$2.44B$937.82M-4.14988Analyst Forecast
Short Interest ↓
News Coverage
Deciphera Pharmaceuticals
2.784 of 5 stars
2.78 / 5 stars

Related Companies and Tools

This page (NASDAQ:WVE) was last updated on 7/15/2024 by Staff

From Our Partners